JP7727385B2 - ペプチド核酸コンジュゲート - Google Patents

ペプチド核酸コンジュゲート

Info

Publication number
JP7727385B2
JP7727385B2 JP2020532690A JP2020532690A JP7727385B2 JP 7727385 B2 JP7727385 B2 JP 7727385B2 JP 2020532690 A JP2020532690 A JP 2020532690A JP 2020532690 A JP2020532690 A JP 2020532690A JP 7727385 B2 JP7727385 B2 JP 7727385B2
Authority
JP
Japan
Prior art keywords
pna
antibody
conjugate
sequence
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020532690A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021507695A5 (https=
JP2021507695A (ja
Inventor
アオウーネ バーホウミ，
ルイ ホン，
Original Assignee
ヴェンタナ メディカル システムズ， インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/066976 external-priority patent/WO2018118759A1/en
Application filed by ヴェンタナ メディカル システムズ， インク． filed Critical ヴェンタナ メディカル システムズ， インク．
Publication of JP2021507695A publication Critical patent/JP2021507695A/ja
Publication of JP2021507695A5 publication Critical patent/JP2021507695A5/ja
Priority to JP2023077482A priority Critical patent/JP2023113642A/ja
Application granted granted Critical
Publication of JP7727385B2 publication Critical patent/JP7727385B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/10—Oligonucleotides as tagging agents for labelling antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2020532690A 2017-12-18 2018-06-13 ペプチド核酸コンジュゲート Active JP7727385B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023077482A JP2023113642A (ja) 2017-12-18 2023-05-09 ペプチド核酸コンジュゲート

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762599810P 2017-12-18 2017-12-18
USPCT/US2017/066976 2017-12-18
US62/599,810 2017-12-18
PCT/US2017/066976 WO2018118759A1 (en) 2016-12-19 2017-12-18 Peptide nucleic acid conjugates
PCT/EP2018/065697 WO2019120635A1 (en) 2017-12-18 2018-06-13 Peptide nucleic acid conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023077482A Division JP2023113642A (ja) 2017-12-18 2023-05-09 ペプチド核酸コンジュゲート

Publications (3)

Publication Number Publication Date
JP2021507695A JP2021507695A (ja) 2021-02-25
JP2021507695A5 JP2021507695A5 (https=) 2021-07-26
JP7727385B2 true JP7727385B2 (ja) 2025-08-21

Family

ID=66992513

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020532690A Active JP7727385B2 (ja) 2017-12-18 2018-06-13 ペプチド核酸コンジュゲート
JP2023077482A Pending JP2023113642A (ja) 2017-12-18 2023-05-09 ペプチド核酸コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023077482A Pending JP2023113642A (ja) 2017-12-18 2023-05-09 ペプチド核酸コンジュゲート

Country Status (5)

Country Link
US (3) US11603388B2 (https=)
EP (1) EP3727470B1 (https=)
JP (2) JP7727385B2 (https=)
CN (1) CN111491667A (https=)
WO (1) WO2019120635A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3554556B1 (en) * 2016-12-19 2022-03-09 Ventana Medical Systems, Inc. Peptide nucleic acid conjugates
JP7727385B2 (ja) * 2017-12-18 2025-08-21 ヴェンタナ メディカル システムズ， インク． ペプチド核酸コンジュゲート
KR102923870B1 (ko) * 2019-09-02 2026-02-06 주식회사 시선바이오머티리얼스 신규한 pna 올리고머, 이의 dna 메틸화 검출용도 및 이를 이용한 dna 메틸화 검출방법
CN115177740A (zh) * 2021-04-01 2022-10-14 安升（上海）医药科技有限公司 核酸自组装介导的adc药物的构建方法及应用
EP4653542A1 (en) * 2024-05-21 2025-11-26 Leica Microsystems CMS GmbH Label, marker and method for analysing a biological sample

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016126748A1 (en) 2015-02-02 2016-08-11 Two Pore Guys, Inc. Labile linkers for biomarker detection
JP2016527199A (ja) 2013-06-11 2016-09-08 ポルタゲ ファーマシューティカルス エルティーディー． 生物学的に活性な特異的カーゴペプチドと結合したヒト由来の細胞透過性ペプチドの構造、製造および使用
JP2017505623A (ja) 2014-01-30 2017-02-23 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 生物切断性コンジュゲートを有するポリオリゴマー化合物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595707A (en) 1990-03-02 1997-01-21 Ventana Medical Systems, Inc. Automated biological reaction apparatus
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
DE4331012A1 (de) 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
US5786571A (en) 1997-05-09 1998-07-28 Lexmark International, Inc. Wrapped temperature sensing assembly
CA2320390C (en) 1998-02-11 2010-06-08 Applied Biosystems, Llc Pna and dna conjugates and methods for preparation thereof
US6582962B1 (en) 1998-02-27 2003-06-24 Ventana Medical Systems, Inc. Automated molecular pathology apparatus having independent slide heaters
JP3847559B2 (ja) 1998-02-27 2006-11-22 ベンタナ・メデイカル・システムズ・インコーポレーテツド 独立スライド加熱器を有する自動化分子病理学装置
US20030211630A1 (en) 1998-02-27 2003-11-13 Ventana Medical Systems, Inc. Automated molecular pathology apparatus having independent slide heaters
US6670113B2 (en) 2001-03-30 2003-12-30 Nanoprobes Enzymatic deposition and alteration of metals
CN100513414C (zh) 2001-08-27 2009-07-15 杰南技术公司 进行抗体表达和装配的系统
US7280812B2 (en) 2003-06-06 2007-10-09 Interdigital Technology Corporation Digital baseband receiver with DC discharge and gain control circuits
DK1636586T3 (da) 2003-06-24 2009-11-23 Ventana Med Syst Inc Enzymkatalyseret metaldeponering til foröget in situ-detektion af immunhistokemisker epitoper og nucleinsyresekvenser
US8592219B2 (en) 2005-01-17 2013-11-26 Gyros Patent Ab Protecting agent
SE0400181D0 (sv) 2004-01-29 2004-01-29 Gyros Ab Segmented porous and preloaded microscale devices
US7244665B2 (en) 2004-04-29 2007-07-17 Micron Technology, Inc. Wafer edge ring structures and methods of formation
WO2006022639A1 (en) 2004-07-21 2006-03-02 Applera Corporation Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof
CA2606018A1 (en) 2005-04-28 2006-11-02 Ventana Medical Systems, Inc. Nanoparticle conjugates
DE602006020577D1 (de) 2005-07-01 2011-04-21 Dako Denmark As Monomere und polymere linker zur konjugierung von biologischen molekülen und anderen stoffen
US20070010014A1 (en) 2005-07-06 2007-01-11 General Electric Company Compositions and methods for enhanced delivery to target sites
US20070134739A1 (en) 2005-12-12 2007-06-14 Gyros Patent Ab Microfluidic assays and microfluidic devices
DK2444807T3 (da) 2006-11-01 2014-08-11 Ventana Med Syst Inc Mono- og dinitropyrazolhaptenkonjugater
US9371348B2 (en) * 2006-11-27 2016-06-21 The Trustees Of The University Of Pennsylvania Photocleavable oligonucleotide and uses thereof
EP2167963B1 (en) 2007-05-23 2019-04-17 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
CN101868728A (zh) 2007-11-21 2010-10-20 鹿特丹伊拉斯姆斯大学医疗中心 改进的fret探针及其应用
EP2334827B1 (en) 2008-08-22 2015-03-11 Ventana Medical Systems, Inc. Method for chromogenic detection of two or more target molecules in a single sample
JP5634405B2 (ja) 2008-10-07 2014-12-03 ユィロス・パテント・アクチボラグＧｙｒｏｓ Ｐａｔｅｎｔ ＡＢ 試料中のアナライトの検出のための半逐次アッセイ
CA2842661C (en) 2009-10-19 2016-02-23 Ventana Medical Systems, Inc. Imaging system and techniques
WO2012138955A2 (en) 2011-04-08 2012-10-11 Ly Danith H CONFORMATIONALLY-PREORGANIZED, MiniPEG-CONTAINING GAMMA-PEPTIDE NUCLEIC ACIDS
CN105204152B (zh) 2011-09-09 2018-10-26 文塔纳医疗系统公司 成像系统、盒和使用其的方法
ES2678211T3 (es) 2012-03-27 2018-08-09 Ventana Medical Systems, Inc. Conjugados de señalización y procedimientos de uso
ES2754177T3 (es) 2013-06-12 2020-04-16 Massachusetts Gen Hospital Métodos para la detección multiplexada de moléculas diana y sus usos
EP3096796A1 (en) * 2014-01-21 2016-11-30 The United States of America, as represented by The Secretary, Department of Health and Human Services cGAP-PNA MULTIVALENT PEPTIDE NUCLEIC ACID LIGAND DISPLAY
CN104031129A (zh) * 2014-07-07 2014-09-10 玉峰惠仁生物医药科技（北京）有限公司 用于检测金黄色葡萄球菌和/或表皮葡萄球菌的肽核酸探针组及其试剂盒、使用方法、用途
MA42157A (fr) 2015-04-23 2018-02-28 Geron Corp Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent
WO2018002015A1 (en) 2016-06-28 2018-01-04 Ventana Medical Systems, Inc. New colors for chromogenic ihc and ish staining with multi-dye quinone methide and tyramide conjugates
JP7727385B2 (ja) * 2017-12-18 2025-08-21 ヴェンタナ メディカル システムズ， インク． ペプチド核酸コンジュゲート

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016527199A (ja) 2013-06-11 2016-09-08 ポルタゲ ファーマシューティカルス エルティーディー． 生物学的に活性な特異的カーゴペプチドと結合したヒト由来の細胞透過性ペプチドの構造、製造および使用
JP2017505623A (ja) 2014-01-30 2017-02-23 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 生物切断性コンジュゲートを有するポリオリゴマー化合物
WO2016126748A1 (en) 2015-02-02 2016-08-11 Two Pore Guys, Inc. Labile linkers for biomarker detection

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CAO, Y.-C., et al., Quantum dots high fluorescent signal amplification immunoassay using branched DNA and peptide nucleic acid conjugated antibody, Analyst, 2011, DOI: 10.1039/C1AN15751E
Ethan A. Englund, et al., γ-SUBSTITUTED PEPTIDE NUCLEIC ACIDS CONSTRUCTED FROM L-LYSINE ARE A VERSATILE SCAFFOLD FOR MULTIFUNCTIONAL DISPLAY, ANGEWANDTE CHEMIE INTERNATIONAL EDITION, 2007年02月19日, Vol.46, No.9, pp.1414 - 1418, http://dx.doi.org/10.1002/anie.200603483
SAHU BICHISMITA, et al., SYNTHESIS AND CHARACTERIZATION OF CONFORMATIONALLY PREORGANIZED, (R)-DIETHYLENE GLYCOL-CONTAINING γ-PEPTIDE NUCLEIC ACIDS WITH SUPERIOR HYBRIDIZATION PROPERTIES AND WATER SOLUBILITY, JOURNAL OF ORGANIC CHEMISTRY, 米国, AMERICAN CHEMICAL SOCIETY, 2011年07月15日, Vol.76, No.14, pp.5614 - 5627, http://dx.doi.org/10.1021/jo200482d
STEPHAN DICKGIESSER, et al., SELF-ASSEMBLED HYBRID APTAMER-FC CONJUGATES FOR TARGETED DELIVERY: A MODULAR CHEMOENZYMATIC APPROACH, ACS CHEMICAL BIOLOGY, 米国, AMERICAN CHEMICAL SOCIETY, 2015年09月18日, Vol.10, No.9, pp;2158 - 2165, http://dx.doi.org/10.1021/acschembio.5b00315
STEPHANIE A. KAZANE, et al., SELF-ASSEMBLED ANTIBODY MULTIMERS THROUGH PEPTIDE NUCLEIC ACID CONJUGATION, JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, 2013年01月09日, Vol.135, No.1, pp.340 - 346, http://dx.doi.org/10.1021/ja309505c

Also Published As

Publication number Publication date
US20230174585A1 (en) 2023-06-08
WO2019120635A1 (en) 2019-06-27
US12173031B2 (en) 2024-12-24
EP3727470A1 (en) 2020-10-28
CN111491667A (zh) 2020-08-04
EP3727470B1 (en) 2024-11-20
US20250066426A1 (en) 2025-02-27
US20200339633A1 (en) 2020-10-29
JP2021507695A (ja) 2021-02-25
JP2023113642A (ja) 2023-08-16
US11603388B2 (en) 2023-03-14

Similar Documents

Publication Publication Date Title
US12173031B2 (en) Peptide nucleic acid conjugates
CN109642898B (zh) 用多染料醌甲基化物和酪酰胺缀合物的显色ihc和ish染色的新颜色
US20190018018A1 (en) Signaling conjugates and methods of use
JP2019532012A (ja) Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用
JP6880001B2 (ja) ケージドハプテンを使用するホルマリン固定パラフィン包埋組織におけるタンパク質近接アッセイ
JP7743561B2 (ja) クマリン系架橋試薬
US20260056191A1 (en) Polymers and conjugates comprising the same
US20230151361A1 (en) Peptide nucleic acid conjugates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220922

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230509

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230516

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250516

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250808

R150 Certificate of patent or registration of utility model

Ref document number: 7727385

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150